Low-Dose Naltrexone (LDN) for Immune Modulation — Regenerative Therapies
Opioid receptor antagonist used at 1/10th standard dose for immune modulation and anti-inflammatory effects across multiple chronic conditions.
Overview
Low-dose naltrexone (LDN) refers to the off-label use of the opioid antagonist naltrexone at doses of 1-5 mg/day — approximately 1/10th of the standard FDA-approved dose (50 mg) for opioid and alcohol use disorders. At these low doses, naltrexone produces a brief, transient opioid receptor blockade (4-6 hours) that triggers a compensatory upregulation of endogenous opioid peptides (beta-endorphin, met-enkephalin) and opioid receptor expression. This endorphin rebound enhances immune surveillance and modulates the immune response. Additionally, LDN directly antagonizes Toll-like receptor 4 (TLR4) on microglia and macrophages, reducing pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-1beta) and neuroinflammation. Clinical evidence, while largely from small trials and case series, spans an impressive range of conditions including fibromyalgia (30% pain reduction in an RCT), multiple sclerosis (reduced fatigue, improved quality of life), Crohn disease (remission induction in a pilot RCT), chronic fatigue syndrome, and complex regional pain syndrome. LDN is typically prescribed through compounding pharmacies in capsule or liquid form. Its low side effect profile, negligible abuse potential, and low cost have made it popular in integrative and functional medicine, though large-scale Phase 3 trials are still needed.
Indications
- Emerging evidence: Fibromyalgia pain reduction (30% improvement in RCT)
- Emerging evidence: Multiple sclerosis (fatigue, quality of life)
- Emerging evidence: Crohn disease (clinical remission in pilot RCT)
- Emerging evidence: Chronic fatigue syndrome / ME-CFS
- Emerging evidence: Complex regional pain syndrome (CRPS)
- Off-label: Various autoimmune conditions (Hashimoto thyroiditis, rheumatoid arthritis)
Mechanism of Action
Low-dose naltrexone briefly blocks mu and delta opioid receptors for 4-6 hours, creating a temporary perception of endorphin deficiency
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Naltrexone (compounded) | 1.5 mg | Once daily at bedtime | Starting dose; titrate up over 2-4 weeks |
| Naltrexone (compounded) | 3 mg | Once daily at bedtime | Intermediate dose; commonly used for autoimmune conditions |
| Naltrexone (compounded) | 4.5 mg | Once daily at bedtime | Standard target dose for most LDN protocols |
| Naltrexone cream (compounded) | 1-4% | Applied to affected area | Topical LDN for localized pain or dermatologic conditions |
Evidence Grade
GRADE C
Safety & Contraindications
- Absolutely contraindicated with concurrent opioid medications — will precipitate withdrawal
- Must be opioid-free for 7-14 days before initiating LDN
- Vivid dreams and sleep disturbances common in first 1-2 weeks (often self-limiting)
- Mild headache, nausea, and anxiety reported during initiation
- Compounding pharmacy quality varies — choose PCAB-accredited pharmacies
- Not FDA-approved at low doses; all use is off-label